CARA (Cara Therapeutics) Price-to-Operating-Cash-Flow : (As of May. 27, 2025)

View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Price-to-Operating-Cash-Flow?

As of today (2025-05-27), Cara Therapeutics's share price is $15.96. Cara Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2024 was $-40.11. Hence, Cara Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Cara Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Cara Therapeutics's highest Price-to-Operating-Cash-Flow Ratio was 1642.29. The lowest was 28.47. And the median was 117.19.

CARA's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.23
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Cara Therapeutics's Cash Flow from Operations per share for the three months ended in Dec. 2024 was $-2.65. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2024 was $-40.11.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 2.10% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -12.60% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was -1.00% per year.

During the past 13 years, Cara Therapeutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 59.80% per year. The lowest was -145.80% per year. And the median was 2.85% per year.

Cara Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Cara Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cara Therapeutics Price-to-Operating-Cash-Flow Chart

Cara Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

Cara Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cara Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Cara Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cara Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Cara Therapeutics Price-to-Operating-Cash-Flow Calculation

Cara Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	15.96	/	-40.105
	=

Cara Therapeutics's Share Price of today is $15.96.
Cara Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.11.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Cara Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Cara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

0HTC:UK

Address

400 Atlantic Street, Suite 500, Stamford, CT, USA, 06901

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Executives

Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Joana Goncalves	officer: Chief Medical Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion	officer: Sec'y; Chief Compliance & G.C.	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Menzaghi Frederique Ph.d.	officer: VP-Research & Development	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Ryan D Maynard	officer: Chief Financial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Moltke Lisa Von	director	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum	director	675 ALMANOR AVE, SUNNYVALE CA 94085
Csl Ltd	10 percent owner
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr	director
Thomas Charles Reilly	officer: Chief Financial Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd.	10 percent owner	RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027